Currently, there are 279.35M common shares owned by the public and among those 272.92M shares have been available to trade.
Insiders at the company have transacted a total of 81 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 61 of these insider trades were purchases, accounting for 4,368,089 shares. Insider sales of the common stock occurred on 20 occasions, with total insider shares sold totaling 4,275,583 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The company’s stock has a 5-day price change of 6.73% and 98.41% over the past three months. IMGN shares are trading 5.33% year to date (YTD), with the 12-month market performance up to 586.37% higher. It has a 12-month low price of $3.61 and touched a high of $31.24 over the same period. IMGN has an average intraday trading volume of 5.74 shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 5.57%, 7.54%, and 65.54% respectively.
Institutional ownership of Immunogen, Inc. (NASDAQ: IMGN) shares accounts for 87.35% of the company’s 279.35M shares outstanding.
It has a market capitalization of $8.72B and a beta (3y monthly) value of 1.19. The earnings-per-share (ttm) stands at -$0.30. Price movements for the stock have been influenced by the stock’s volatility, which stands at 0.53% over the week and 0.59% over the month.
Analysts forecast that Immunogen, Inc. (IMGN) will achieve an EPS of $ImmunoGen, Inc. for the current quarter, $31.23 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Inogen, Inc while analysts give the company a high EPS estimate of $Imunon, Inc.. Comparatively, EPS for the current quarter was $Immuron Limited a year ago. Earnings per share for the fiscal year are expected to increase by 108.48%, and 402.04% over the next financial year.
Looking at the support for the IMGN, a number of firms have released research notes about the stock. Guggenheim stated their Neutral rating for the stock in a research note on December 01, 2023, with the firm’s price target at $25-$31.
